- Active not recruitingPHASE3
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
This study looks at a new medicine called ocrelizumab for children and teenagers aged 10-17 with a type of MS called relapsing-remitting multiple sclerosis (RRMS). It compares ocrelizumab to an existing medicine, fingolimod, to see how safe and effective it is over a period of time.
For: Relapsing-Remitting Multiple SclerosisUnited States · Argentina · Australia - Active not recruitingPHASE3
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
This study looks at how safe and effective two medicines, fingolimod and interferon beta-1a, are for young people aged 10-17 with multiple sclerosis (MS). It compares them to see which works best and is safest.
For: Multiple SclerosisUnited States · Australia · Austria - Active not recruitingPHASE3
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
This study looks at two new medicines, ofatumumab and siponimod, for children and teenagers aged 10-17 with multiple sclerosis (MS). It compares them to a medicine called fingolimod to see if they are safe and work well.
For: Multiple Sclerosis (MS)United States · Argentina · Australia